Oncolytic Virus Preclinical Studies at Creative Biolabs Accelerate Time to Market for OV Therapy Research

Oncolytic viruses (OVs) represent a new class of therapeutic agents that promote anti-tumor responses through a dual mechanism of action dependent on selective tumor cell killing and anti-tumor immunity induction. However, OV development faces unique challenges, among which an important one is novel biosafety concerns related to viral persistence in patients.

To facilitate OV research of worldwide clients, Creative Biolabs now offers a new range of oncolytic virus in vivo preclinical study services to help prove the safety and efficacy of the engineered OV, including but not limited to the construction of xenograft/syngeneic animal models, immunogenicity tests, biodistribution/PK tests, efficacy studies, and toxicology studies.

A set of immuno-compromised animal models are permissive to different kinds of OV infection, including nude, nonobese diabetic-severe combined immunodeficiency (NOD-SCID), and NOD SCID gamma (NSG) mice. Creative Biolabs can also develop customized animal models for proof-of-concept (POC) and toxicology studies in accordance with the virus type.

Immunogenicity is one of the most prominent problems when developing oncolytic viral drugs. The expert team at Creative Biolabs is fully equipped to provide OV immunogenicity tests including innate immune response test, neutralization antibody production test, and anti-drug antibody (ADA) test.

As biodistribution study is directly related to OV efficacy, off-target effects, and immunogenicity, scientists at Creative Biolabs have established efficient strategies to study the biodistribution of OV in circulatory system, target organs, and major vital organs.

Creative Biolabs also offers OV in vivo efficacy studies ranging from antitumor effect, transgene expression and transgene function, immunological analysis, histological and pathological analysis, to clinical observation, which will provide comprehensive information for later stage development, including optimization of administration route, dose, and clinical trial design.

In addition, various assays are also available to analyze the toxicity of OV and the expressed transgene, in which the shedding study, clinical observation, clinical pathology, gross organ pathology, histopathology, transgene-specific toxicity study, as well as off-target toxicity study, are all taken into consideration.

“If you are looking for ways to streamline operations and exploit new technology to reduce costs and increase efficiency for your oncolytic virus research, we are always here and ready to customize a project to expand your experimental possibilities.” said a senior scientist at Creative Biolabs.

More information about OV services and products can be found on https://www.creative-biolabs.com/oncolytic-virus.

About Creative Biolabs

Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is dedicated to offering comprehensive, end-to-end oncolytic virus therapy development services. The whole pipeline covers OV engineering, in vitro validation study, in vivo preclinical study, and disease-specific oncolytic virotherapy development. A list of pre-made OV products and oncolytic adenovirus construction kits is also available.

Media Contact

Company Name
Creative Biolabs
Contact Name
Candy Swift
New York
United States

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No PITCH SCOOP journalist was involved in the writing and production of this article.